Changxian Shen

发表

TOR Signaling Is a Determinant of Cell Survival in Response to DNA Damage

M. Bjornsti, Changxian Shen, C. S. Lancaster, 2007, Molecular and Cellular Biology.

Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.

Markus Schwaiger, Ken Herrmann, Hans-Jürgen Wester, 2009, Methods.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia

M. Caligiuri, C. Bloomfield, C. Croce, 2017, Proceedings of the National Academy of Sciences.

The Interplay of Key Phospholipid Biosynthetic Enzymes and the Yeast V-ATPase Pump and their Role in Programmed Cell Death

Changxian Shen, Goldie Libby Sherr, Goldie Libby Sherr, 2021 .

Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy

T. Williams, Changxian Shen, Qiang Chen, 2021, Annals of translational medicine.

Targeting FANCD2 for therapy sensitization

P. Houghton, Changxian Shen, 2014, Oncotarget.

Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.

H. Schirrmeister, S. Reske, A. Guhlmann, 2002, Cancer biotherapy & radiopharmaceuticals.

Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy.

H. Schirrmeister, A. Buck, S. Reske, 2003, Cancer biotherapy & radiopharmaceuticals.

Adenovirus-delivered siRNA.

S. Reske, Changxian Shen, 2004, Methods in molecular biology.

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair

X. Mo, A. Webb, T. Williams, 2021, Nucleic acids research.

Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells

A. Buck, S. Reske, Changxian Shen, 2003, Cancer Gene Therapy.

Regulation of DNA duplication by the mTOR signaling pathway

P. Houghton, T. Williams, Changxian Shen, 2021, Cell cycle.

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.

P. Houghton, C. Pelloski, Changxian Shen, 2013, Cancer research.

Regulation of FANCD 2 by the mTOR Pathway Contributes to theResistanceofCancerCells toDNADouble-StrandBreaks

P. Houghton, C. Pelloski, Changxian Shen, 2013 .

2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double strand breaks

P. Houghton, C. Pelloski, Changxian Shen, 2013 .

mTOR Signaling Upregulates CDC6 via Suppressing miR-3178 and Promotes the Loading of DNA Replication Helicase

P. Houghton, T. Williams, Changxian Shen, 2019, Scientific Reports.

The mTOR pathway negatively controls ATM by up-regulating miRNAs

P. Houghton, Changxian Shen, 2013, Proceedings of the National Academy of Sciences.

Gene silencing by adenovirus‐delivered siRNA

S. Reske, Changxian Shen, M. Winkler, 2003, FEBS letters.

Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo

Michael C. Ostrowski, C. Shapiro, S. Majumder, 2015, Genes & development.

Chromosome instability and tumor lethality suppression in carcinogenesis

A. Buck, S. Reske, Changxian Shen, 2008, Journal of cellular biochemistry.

Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells.

A. Buck, S. Reske, Changxian Shen, 2009, Anticancer research.

Inhibition of MEK confers hypersensitivity to X‐radiation in the context of BRAF mutation in a model of childhood astrocytoma

P. Houghton, Paul D. Smith, X. Mo, 2015, Pediatric blood & cancer.

LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma

Tianyu Li, T. Williams, Changxian Shen, 2019, Molecular Cancer Therapeutics.

Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells

R. Garzon, P. Houghton, Changxian Shen, 2017, Scientific Reports.

Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy

Steven H. Lin, Tianyu Li, Junran Zhang, 2020, Clinical Cancer Research.

Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair

M. Saji, M. Ringel, S. Jhiang, 2019, Clinical Cancer Research.

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters

Torsten Mattfeldt, Jörg Kotzerke, Gerhard Glatting, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia

C. Bloomfield, R. Garzon, Changxian Shen, 2019, Clinical Cancer Research.

Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.

W. Duan, A. Webb, T. Williams, 2021, Molecular cancer research : MCR.

PTEN mutation: many birds with one stone in tumorigenesis.

S. Reske, Changxian Shen, Yonggang Zhou, 2008, Anticancer research.

P53 suppresses ribonucleotide reductase via inhibiting mTORC1

R. Garzon, P. Houghton, Changxian Shen, 2017, Oncotarget.

FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene

P. Houghton, A. Chakravarti, W. Duan, 2014, Clinical Cancer Research.

Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1.

M. Venere, Changxian Shen, T. DeWees, 2023, Cancer letters.

Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?

T. Mattfeldt, H. Schirrmeister, S. Reske, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy (SBRT).

A. Webb, Changxian Shen, G. DeNicola, 2023, Cancer.